June 1, 2024 Issue of JAMA Oncology

June 2024, Vol 10, No. 6, Pages 697-835

Original Investigation

FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial

David Tougeron, MD, PhD; Laetitia Dahan, MD, PhD; Ludovic Evesque, MD; et al.

Abstract Full Text

open access

JAMA Oncol. 2024;10(6):709-717. doi:10.1001/jamaoncol.2024.0207

This randomized clinical trial examines the efficacy of 1 or 2 immune checkpoint inhibitors combined with FOLFIRI in the treatment of advanced gastric/GEJ adenocarcinoma.

Editorial
Immunotherapy in Gastric Cancer鈥擟hoosing Methods or Results
Thierry Alcindor, MD, MSc

JAMA Oncol

Second Primary Breast Cancer in Young Breast Cancer Survivors

Kristen D. Brantley, PhD, MPH; Shoshana M. Rosenberg, ScD, MPH; Laura C. Collins, MD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(6):718-725. doi:10.1001/jamaoncol.2024.0286

This cohort study examines the risk of a second primary breast cancer in women who were aged 40 years or younger when first diagnosed with breast cancer.

Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer

Jeffrey J. Tosoian, MD, MPH; Yuping Zhang, PhD; Lanbo Xiao, PhD; et al.

Abstract Full Text

open access

JAMA Oncol. 2024;10(6):726-736. doi:10.1001/jamaoncol.2024.0455

This report describes the development of an 18-gene urine panel for high-grade prostate cancer and validates its external performance relative to current guideline-endorsed biomarkers.

Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer: The POHIM-CCRT Nonrandomized Controlled Trial

Won Kyung Cho, MD; Won Park, MD; Sang-Won Kim, MD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(6):737-743. doi:10.1001/jamaoncol.2024.0565

This nonrandomized controlled trial investigates the acute toxic effects of treatment with hypofractionated pelvic intensity-modulated radiotherapy and concurrent chemotherapy among women who experienced lymph node metastasis, parametrial invasion, or positive resection margins after radical hysterectomy for treatment of confirmed cervical cancer.

Invited Commentary
Interpreting the Findings of the POHIM-CCRT Trial
Mark E. Bernard, MD

JAMA Oncol

Magnetic Resonance Imaging in Prostate Cancer Screening: A Systematic Review and Meta-Analysis

Tamás Fazekas, MD; Sung Ryul Shim, MPH, PhD; Giuseppe Basile, MD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(6):745-754. doi:10.1001/jamaoncol.2024.0734

This systematic review and meta-analysis examines evidence regarding screening pathways incorporating magnetic resonance imaging with targeted biopsy and assess their diagnostic value compared with prostate-specific antigen鈥揵ased screening with systematic biopsy strategies.

Nivolumab鈥�+鈥塈pilimumab as Immunotherapeutic Boost in Metastatic Urothelial Carcinoma: A Nonrandomized Clinical Trial

Marc-Oliver Grimm, MD; Martin Schostak, MD, PhD; Christine Barbara Grün, MD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(6):755-764. doi:10.1001/jamaoncol.2024.0938

This nonrandomized clinical trial evaluates the efficacy and safety of a tailored approach with nivolumab plus ipilimumab as an immunotherapeutic boost in patients with metastatic urothelial carcinoma.

Precision Colorectal Cancer Fecal Immunological Test Screening With Fecal-Hemoglobin-Concentration鈥揋uided Interscreening Intervals

Amy Ming-Fang Yen, PhD; Chen-Yang Hsu, PhD; Ting-Yu Lin, PhD; et al.

Abstract Full Text

open access

JAMA Oncol. 2024;10(6):765-772. doi:10.1001/jamaoncol.2024.0961

This cohort study examines the applicability of personalized colorectal cancer (CRC) screening with fecal-hemoglobin (f-Hb)-guided screening intervals to reduce the number of fecal immunological tests and colonoscopy, as well as determine if it demonstrates equivalent efficacy as universal biennial screening.

Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy

Tafadzwa L. Chaunzwa, MD; Jack M. Qian, MD; Qin Li, PhD; et al.

Abstract Full Text

free access

JAMA Oncol. 2024;10(6):773-783. doi:10.1001/jamaoncol.2024.1120

This cohort study examines the association of body composition with oncologic outcomes in patients receiving immunotherapy for advanced or metastatic non鈥搒mall cell lung cancer.

Brief Report

Patient-Reported Outcomes as a Recruitment Strategy for Clinical Trial Enrollment

Nicholas P. Verdini, BS; Karolina L. Bryl, PhD; Raymond E. Baser, MS; et al.

Abstract Full Text

JAMA Oncol. 2024;10(6):784-788. doi:10.1001/jamaoncol.2024.0280

This study examines the association between electronic patient-reported outcome鈥損rompted recruitment strategies and clinical trial enrollment.

Adherence to American Cancer Society Nutrition and Physical Activity Guidelines Among Cancer Survivors

Carter Baughman, MD; Kathryn Norman, MD; Kenneth Mukamal, MD, MPH

Abstract Full Text

JAMA Oncol. 2024;10(6):789-792. doi:10.1001/jamaoncol.2024.0470

This cross-sectional study uses data from the Behavioral Risk Factor Surveillance System to evaluate adherence to the American Cancer Society (ACS) nutrition and physical activity guidelines among cancer survivors.

Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy

Giacomo Montagna, MD, MPH; Mary M. Mrdutt, MD, MS; Susie X. Sun, MD; et al.

Abstract Full Text

JAMA Oncol. 2024;10(6):793-798. doi:10.1001/jamaoncol.2024.0578

This cohort study examines oncological outcomes after sentinel lymph node biopsy with dual-tracer mapping or targeted axillary dissection.

Research Letter

Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia

Laurent Phely, MD; Luca Hensen, PhD; Christoph Faul, MD; et al.

Abstract Full Text

open access

JAMA Oncol. 2024;10(6):821-824. doi:10.1001/jamaoncol.2024.0473

This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.

Gefitinib vs Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Variant Lung Cancer鈥擫ong-Term Results of a Randomized Clinical Trial

Vanita Noronha, MBBS, MD, DM; Vijay Patil, MBBS, MD, DM; Nandini Menon, MBBS, MD, DM; et al.

Abstract Full Text

JAMA Oncol. 2024;10(6):824-826. doi:10.1001/jamaoncol.2024.0584

This randomized clinical trial examines whether adding chemotherapy with pemetrexed and carboplatin to gefitinib improves survival among patients with epidermal growth factor receptor (EGFR)鈥搗ariant non鈥搒mall cell lung cancer.

T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

Ryan Storgard, MSc; Kai Rejeski, MD; Miguel-Angel Perales, MD; et al.

Abstract Full Text

has audio

JAMA Oncol. 2024;10(6):826-828. doi:10.1001/jamaoncol.2024.0662

This cohort study assesses the increase in second primary malignant neoplasms and T-cell malignant neoplasm cases associated with chimeric antigen receptor鈥揟 cells.

Podcast: T-Cell Malignant Neoplasms After Chimeric Antigen Receptor T-Cell Therapy

Special Communication

American Radium Society Appropriate Use Criteria for Unresectable Locally Advanced Non鈥揝mall Cell Lung Cancer

George Rodrigues, MD, PhD; Kristin A. Higgins, MD; Andreas Rimner, MD; et al.

Abstract Full Text

has active quiz

JAMA Oncol. 2024;10(6):799-806. doi:10.1001/jamaoncol.2024.0294

This Special Communication discusses case-referenced consensus and evidence-based guidelines to inform clinical practice in unresectable locally advanced non鈥搒mall cell lung cancer (NSCLC).

Review

Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review

Maha Hussain, MD; Karim Fizazi, MD, PhD; Neal D. Shore, MD; et al.

Abstract Full Text

has active quiz

JAMA Oncol. 2024;10(6):807-820. doi:10.1001/jamaoncol.2024.0591

This review assesses current evidence and emerging treatment strategies for improved survival among patients with metastatic hormone-sensitive prostate cancer and offers recommendations for clinical practice application.

Viewpoint

Ovarian Cancer Isn鈥檛 Just a White Woman鈥檚 Disease

Anna Jo Bodurtha Smith, MD, MPH, MSc; Elizabeth A. Howell, MD, MPP; Emily M. Ko, MD, MSCR

Abstract Full Text

JAMA Oncol. 2024;10(6):697-698. doi:10.1001/jamaoncol.2024.0191

This Viewpoint highlights the need for recognition that ovarian cancer affects women from racial and ethnic minority groups worldwide and that the rates of ovarian cancer are increasing in those populations while decreasing among White women.

Using Nerve Blocks for Addressing Radiation-Induced Pain During Pelvic Cancer Treatment

Jolinta Y. Lin, MD; Jill S. Remick, MD; Vinita Singh, MD, MS

Abstract Full Text

JAMA Oncol. 2024;10(6):698-699. doi:10.1001/jamaoncol.2024.0304

This Viewpoint discusses the use of nerve blocks for pain during pelvic cancer treatment.

Policy Priorities in Cancer Care for Transgender People

Alicia C. Smart, MD; Michael J. Yunes, MD; Karen M. Winkfield, MD, PhD

Abstract Full Text

JAMA Oncol. 2024;10(6):699-701. doi:10.1001/jamaoncol.2024.0451

This Viewpoint calls for health care systems, oncologists, and staff to prioritize and adopt policies that are inclusive and respectful of transgender patients with cancer.

Editorial